A case report of uterine leiomyosarcoma
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20250532Keywords:
Uterine leiomyosarcoma, Menstrual disorder, Uterine sarcomaAbstract
The most prevalent benign tumour in women is uterine leiomyoma. Smooth muscle cells give rise to the uncommon malignant tumour known as uterine leiomyosarcoma. It makes up 1% of all uterine cancers. One out of every 800 women who are thought to have leiomyoma actually has a sarcoma. Uterine leiomyosarcoma is usually diagnosed by histopathological examination and surgery is the only treatment. We describe a 48-year-old woman who had heavy menstrual flow and was initially diagnosed with uterine leiomyoma. Histological analysis revealed that she actually had uterine leiomyosarcoma.
Metrics
References
Kaur K, Kaur P, Kaur A, Singla A. Uterine leiomyosarcoma: A case report. J Mid-life Health. 2014;5(4):202-4. DOI: https://doi.org/10.4103/0976-7800.145175
Giuntoli II RL, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, Gostout BS. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecolo Oncol. 2003;5:137-9. DOI: https://doi.org/10.1016/S0090-8258(03)00137-9
Patel SM, Tiwari R, Arora RS, Poddar P, Desai A, Mankad MH. Uterine sarcomas: surgical management, adjuvant therapy and survival outcome. experience at Gujarat cancer and research institute. Indian J Gynecol Oncol. 2019;17:1-7. DOI: https://doi.org/10.1007/s40944-018-0247-0
Corcoran S, Hogan AM, Nemeth T, Bennani F, Sullivan FJ, Khan W, Barry K. Iso lated cutaneous metastasis of uterine leiomyosarcoma: case report and review of literature. Diagnostic Pathol. 2012;7:85-8. DOI: https://doi.org/10.1186/1746-1596-7-85
D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecologic Oncol. 2010;116(1):131-8.
Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Critical reviews in Oncology/Hematol. 2008;65(2):129-42. DOI: https://doi.org/10.1016/j.critrevonc.2007.06.011
Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. The Lancet. 2000;356(9233):881-7. DOI: https://doi.org/10.1016/S0140-6736(00)02677-5
Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, Runowicz CD. Association of tamoxifen and uterine sarcoma. Journal of Clinical Oncology. 2002 Jun 1;20(11):2758-60. DOI: https://doi.org/10.1200/JCO.2002.20.11.2758
Pelmus M, Penault-Llorca F, Guillou L, Collin F, Bertrand G, Trassard M, et al. Prognostic factors in early-stage leiomyosarcoma of the uterus. Int J Gynecol Cancer. 2009;19(3):23-8. DOI: https://doi.org/10.1111/IGC.0b013e3181a1bfbc
D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecologic Oncol. 2010;116(1):131-9. DOI: https://doi.org/10.1016/j.ygyno.2009.09.023
Arend RC, Toboni MD, Montgomery AM, Burger RA, Olawaiye AB, Monk BJ, et al. Systemic treatment of metastatic/recurrent uterine leiomyosarcoma: a changing paradigm. The Oncol. 2018;23(12):1533-45. DOI: https://doi.org/10.1634/theoncologist.2018-0095
Dunphy L, Sheridan G. Uterine leiomyosarcoma: a rare clinical entity. BMJ Case Reports CP. 2021;14(8):244233.
Dunphy L, Sheridan G. Uterine leiomyosarcoma: a rare clinical entity. BMJ Case Reports CP. 2021;14(8):244233. DOI: https://doi.org/10.1136/bcr-2021-244233
Abeler VM, Nenodovic M. Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol. 2011;30(3):236-43. DOI: https://doi.org/10.1097/PGP.0b013e318200caff
Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, et al. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery. ESMO. 2021;6(4):100209. DOI: https://doi.org/10.1016/j.esmoop.2021.100209
Downloads
Published
How to Cite
Issue
Section
